Literature DB >> 20889526

Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Tonia A Douglas1, Siobhain Brennan, Luke Berry, Kaye Winfield, Claire E Wainwright, Keith Grimwood, Stephen M Stick, Peter D Sly.   

Abstract

BACKGROUND: Early detection of Pseudomonas aeruginosa is essential for successful eradication. The accuracy of serum antibodies against specific and multiple P aeruginosa antigens at predicting lower airway infection in young children with cystic fibrosis (CF) was investigated.
METHODS: A commercial P aeruginosa multiple antigen (MAg) ELISA and an in-house exotoxin A (ExoA) ELISA were compared in two populations: a discovery population of 76 children (0.1-7.1 years) undergoing annual bronchoalveolar lavage (BAL)-based microbiological surveillance and a test population of 55 children (0.1-5.6 years) participating in the Australasian CF Bronchoalveolar Lavage Trial.
RESULTS: In the discovery population, P aeruginosa was cultured from BAL fluid (≥10(5) colony-forming units (cfu)/ml) in 15/76 (19.7%) children (median age 1.88 years). Positive MAg and ExoA serological results were found in 38 (50.0%) and 30 (39.5%) children, respectively. Positive (PPV) and negative (NPV) predictive values for serology at diagnosing P aeruginosa infection (≥10(5) cfu/ml) were 0.14 and 0.99 respectively (MAg assay) and 0.11 and 0.98 (ExoA assay). In the test population, P aeruginosa was cultured from BAL fluid (≥10(5) cfu/ml) in 16/55 (29.1%) children (median age 1.86 years) and from oropharyngeal swabs in 32/36 (88.9%). Positive MAg and ExoA serology was detected in 19 (34.5%) and 33 (60.0%) children, respectively. The PPV and NPV of serology were 0.26 and 0.94 respectively (MAg assay) and 0.19 and 0.98 (ExoA assay) and were marginally higher for oropharyngeal cultures.
CONCLUSIONS: Measuring serum antibody responses against P aeruginosa is of limited value for detecting early P aeruginosa infection in young children with CF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889526     DOI: 10.1136/thx.2009.132845

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety.

Authors:  Margaret Rosenfeld; Stephanie Davis; Lyndia Brumback; Stephen Daniel; Ron Rowbotham; Robin Johnson; Sharon McNamara; Renee Jensen; Carol Barlow; Felix Ratjen
Journal:  Pediatr Pulmonol       Date:  2011-03-01

Review 2.  Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It?

Authors:  Sarath C Ranganathan; Graham L Hall; Peter D Sly; Stephen M Stick; Tonia A Douglas
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

3.  Pseudomonas aeruginosa in the Cystic Fibrosis Lung.

Authors:  John King; Ronan Murphy; Jane C Davies
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

4.  Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Authors:  Michael Anstead; Sonya L Heltshe; Umer Khan; Joseph T Barbieri; Markus Langkamp; Gerd Döring; Shimoni Dharia; Ronald L Gibson; Miriam M Treggiari; James Lymp; Margaret Rosenfeld; Bonnie Ramsey
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

Review 5.  Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis.

Authors:  Rashmi Ranjan Das; Sushil Kumar Kabra; Meenu Singh
Journal:  ScientificWorldJournal       Date:  2013-12-30

Review 6.  Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment.

Authors:  Luiz Vicente Ribeiro Ferreira da Silva Filho; Flavia de Aguiar Ferreira; Francisco José Caldeira Reis; Murilo Carlos Amorim de Britto; Carlos Emilio Levy; Otavio Clark; José Dirceu Ribeiro
Journal:  J Bras Pneumol       Date:  2013 Jun-Aug       Impact factor: 2.624

7.  BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study.

Authors:  Ulrika Lindberg; Malin Carlsson; Claes-Göran Löfdahl; Mårten Segelmark
Journal:  Clin Dev Immunol       Date:  2012-12-30

8.  Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease.

Authors:  Emmanuelle Fantino; Catherine L Gangell; Dominik Hartl; Peter D Sly
Journal:  BMC Pulm Med       Date:  2014-02-27       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.